Institution
Clatterbridge Cancer Centre NHS Foundation Trust
Healthcare•Bebington, United Kingdom•
About: Clatterbridge Cancer Centre NHS Foundation Trust is a healthcare organization based out in Bebington, United Kingdom. It is known for research contribution in the topics: Radiation therapy & Cancer. The organization has 589 authors who have published 988 publications receiving 27485 citations. The organization is also known as: Clatterbridge Cancer Centre NHS Foundation Trust & Clatterbridge Centre for Oncology NHS Foundation Trust.
Papers published on a yearly basis
Papers
More filters
••
University of Warwick1, University Hospitals Birmingham NHS Foundation Trust2, University of Salford3, Cardiff University4, Institute of Cancer Research5, Beatson West of Scotland Cancer Centre6, Leeds Teaching Hospitals NHS Trust7, Weston Park Hospital8, Maidstone Hospital9, Royal Bournemouth Hospital10, Derby Hospitals NHS Foundation Trust11, Guy's Hospital12, Cheltenham General Hospital13, Queen Alexandra Hospital14, The Queen's Medical Center15, Musgrove Park Hospital16, Hull and East Yorkshire Hospitals NHS Trust17, Mount Vernon Hospital18, Royal Surrey County Hospital19, East Sussex County Council20, Western General Hospital21, Queen's University Belfast22, East Lancashire Hospitals NHS Trust23, Churchill Hospital24, Telford25, Royal Devon and Exeter Hospital26, Nottingham University Hospitals NHS Trust27, Clatterbridge Cancer Centre NHS Foundation Trust28, Swansea University29
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
1,502 citations
••
Royal Liverpool University Hospital1, University of Liverpool2, Clatterbridge Cancer Centre NHS Foundation Trust3, University of Manchester4, Manchester Royal Infirmary5, The Royal Marsden NHS Foundation Trust6, Weston Park Hospital7, Royal Free Hospital8, St James's University Hospital9, Karolinska Institutet10, Uppsala University11, University of Hamburg12, Royal Surrey County Hospital13, Guy's Hospital14, Hammersmith Hospital15, Beatson West of Scotland Cancer Centre16, Cardiff University17, Queen Elizabeth Hospital Birmingham18, Churchill Hospital19, Derriford Hospital20, University Hospital Coventry21, Heidelberg University22
TL;DR: The adjuvant combination of gem citabine and capecitabine should be the new standard of care following resection for pancreatic ductal adenocarcinoma.
1,378 citations
••
TL;DR: Hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions and is recommended as a new standard of care for external-beam radiotherapy of localised prostate cancer after 5 years follow-up.
Abstract: Summary Background Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a randomised trial comparing conventional and hypofractionated radiotherapy after 5 years follow-up. Methods CHHiP is a randomised, phase 3, non-inferiority trial that recruited men with localised prostate cancer (pT1b–T3aN0M0). Patients were randomly assigned (1:1:1) to conventional (74 Gy delivered in 37 fractions over 7·4 weeks) or one of two hypofractionated schedules (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3·8 weeks) all delivered with intensity-modulated techniques. Most patients were given radiotherapy with 3–6 months of neoadjuvant and concurrent androgen suppression. Randomisation was by computer-generated random permuted blocks, stratified by National Comprehensive Cancer Network (NCCN) risk group and radiotherapy treatment centre, and treatment allocation was not masked. The primary endpoint was time to biochemical or clinical failure; the critical hazard ratio (HR) for non-inferiority was 1·208. Analysis was by intention to treat. Long-term follow-up continues. The CHHiP trial is registered as an International Standard Randomised Controlled Trial, number ISRCTN97182923. Findings Between Oct 18, 2002, and June 17, 2011, 3216 men were enrolled from 71 centres and randomly assigned (74 Gy group, 1065 patients; 60 Gy group, 1074 patients; 57 Gy group, 1077 patients). Median follow-up was 62·4 months (IQR 53·9–77·0). The proportion of patients who were biochemical or clinical failure free at 5 years was 88·3% (95% CI 86·0–90·2) in the 74 Gy group, 90·6% (88·5–92·3) in the 60 Gy group, and 85·9% (83·4–88·0) in the 57 Gy group. 60 Gy was non-inferior to 74 Gy (HR 0·84 [90% CI 0·68–1·03], p NI =0·0018) but non-inferiority could not be claimed for 57 Gy compared with 74 Gy (HR 1·20 [0·99–1·46], p NI =0·48). Long-term side-effects were similar in the hypofractionated groups compared with the conventional group. There were no significant differences in either the proportion or cumulative incidence of side-effects 5 years after treatment using three clinician-reported as well as patient-reported outcome measures. The estimated cumulative 5 year incidence of Radiation Therapy Oncology Group (RTOG) grade 2 or worse bowel and bladder adverse events was 13·7% (111 events) and 9·1% (66 events) in the 74 Gy group, 11·9% (105 events) and 11·7% (88 events) in the 60 Gy group, 11·3% (95 events) and 6·6% (57 events) in the 57 Gy group, respectively. No treatment-related deaths were reported. Interpretation Hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy in 37 fractions and is recommended as a new standard of care for external-beam radiotherapy of localised prostate cancer. Funding Cancer Research UK, Department of Health, and the National Institute for Health Research Cancer Research Network.
849 citations
••
University of Birmingham1, The Royal Marsden NHS Foundation Trust2, HealthPartners3, St George’s University Hospitals NHS Foundation Trust4, University of Leeds5, Glasgow Royal Infirmary6, King's College London7, University of Oxford8, University College London9, University of Manchester10, Chelsea and Westminster Hospital NHS Foundation Trust11, Clatterbridge Cancer Centre NHS Foundation Trust12, St George's, University of London13, Edinburgh Cancer Research Centre14
TL;DR: The clinical and demographic characteristics and COVID-19 outcomes in patients with cancer appear to be principally driven by age, gender, and comorbidities.
846 citations
••
The Royal Marsden NHS Foundation Trust1, University of Birmingham2, University College London3, University of Salford4, University of Manchester5, Guy's and St Thomas' NHS Foundation Trust6, St James's University Hospital7, Kantonsspital St. Gallen8, Beatson West of Scotland Cancer Centre9, Clatterbridge Cancer Centre NHS Foundation Trust10, Cardiff University11, University of Wolverhampton12, University of Glasgow13, University Hospitals Birmingham NHS Foundation Trust14, Queen Alexandra Hospital15, University of London16, Gloucestershire Hospitals NHS Foundation Trust17, Royal Surrey County Hospital18, Queen's University Belfast19, East Lancashire Hospitals NHS Trust20, Freeman Hospital21, Singleton Hospital22, Royal Devon and Exeter Hospital23, Telford24
TL;DR: Radiotherapy to the prostate did not improve overall survival for unselected patients with newly diagnosed metastatic prostate cancer, and the benefit would be greatest in patients with a low metastatic burden.
794 citations
Authors
Showing all 591 results
Name | H-index | Papers | Citations |
---|---|---|---|
David Cunningham | 132 | 1305 | 92200 |
Philip J. Johnson | 94 | 451 | 32899 |
Pieter E. Postmus | 81 | 384 | 24039 |
Axel Heidenreich | 66 | 695 | 24970 |
Michael Brada | 66 | 221 | 13955 |
Neil Pendleton | 61 | 290 | 15976 |
Peter T. Simpson | 46 | 128 | 7792 |
David G. Spiller | 45 | 143 | 7691 |
Daniel H. Palmer | 44 | 235 | 13006 |
Andrew R. Pettitt | 43 | 150 | 7778 |
Alan E. Nahum | 40 | 118 | 5607 |
Muhammed Ashraf Memon | 38 | 139 | 4624 |
Syed A. Hussain | 37 | 199 | 7282 |
Carlo Palmieri | 36 | 163 | 5335 |
John Green | 34 | 166 | 6508 |